Similarly, we provide evidence in clinical practice that low-frequency subclones of heterogeneous, yet already anti-EGFR resistant clones exist in primitive colorectal tumors, with strong implications for targeted treatment planning and design of future clinical trials. This evidence concerns the gene EGFR and colorectal neoplasm.